A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line.

Glucagon-like peptide 1 (GLP-1) secretion from intestinal L-cells is triggered by luminal nutrients. We reported previously that glucose-triggered GLP-1 release from the L-cell model GLUTag involves closure of ATP-sensitive K+ (K(ATP)) channels. We show here that GLP-1 secretion and electrical activity of GLUTag cells is triggered not only by metabolizable sugars (glucose or fructose) but also by the nonmetabolizable monosaccharide methyl-alpha-glucopyranoside. Responses to glucose and methyl-alpha-glucopyranoside were impaired by the sodium-glucose cotransporter (SGLT) inhibitor phloridzin. SLGT1 and 3 were detected in GLUTag cells by RT-PCR. Whereas fructose closed K(ATP) channels, methyl-alpha-glucopyranoside increased the membrane conductance and generated an inward current. Low concentrations of glucose and methyl-alpha-glucopyranoside also triggered small inward currents and enhanced the action potential frequency. We conclude that whereas low concentrations of metabolizable sugars trigger GLP-1 secretion via K(ATP) channel closure, SGLT substrates generate small inward currents as a result of the electrogenic action of the transporter. This transporter-associated current can trigger electrical activity and secretion when the concentration of substrate is high or when outward currents are reduced by metabolic closure of the K(ATP) channels. Electrogenic sugar entry via SGLTs provides a novel mechanism for glucose sensing by neuroendocrine cells.

[1]  K. Takata,et al.  Glucose transporters in the transepithelial transport of glucose. , 1996, Journal of electron microscopy.

[2]  G. Warhurst,et al.  Fatty acid‐induced cholecystokinin secretion and changes in intracellular Ca2+ in two enteroendocrine cell lines, STC‐1 and GLUTag , 2000, The Journal of physiology.

[3]  J. Mayer,et al.  Hyperphagia caused by Cerebral Ventricular Infusion of Phloridzin , 1968, Nature.

[4]  S. Doran,et al.  Effects of intraduodenal glucose and fructose on antropyloric motility and appetite in healthy humans. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[5]  J. Habener,et al.  The glucagon-like peptides. , 1999, Endocrine reviews.

[6]  J M Polak,et al.  Human distribution and release of a putative new gut hormone, peptide YY. , 1985, Gastroenterology.

[7]  F. Matschinsky,et al.  Regulation of Glucose Metabolism in Pancreatic Islets , 1981, Diabetes.

[8]  G. Rutter,et al.  Dynamic imaging of free cytosolic ATP concentration during fuel sensing by rat hypothalamic neurones: evidence for ATP‐independent control of ATP‐sensitive K+ channels , 2002, The Journal of physiology.

[9]  O. Witte,et al.  Expression of the Na+‐d‐Glucose Cotransporter SGLT1 in Neurons , 1997, Journal of neurochemistry.

[10]  P. Rorsman,et al.  The pancreatic beta-cell as a fuel sensor: an electrophysiologist's viewpoint , 1997, Diabetologia.

[11]  B. Glaser,et al.  Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. , 1998, Diabetes.

[12]  F. Ashcroft,et al.  Electrophysiology of the pancreatic beta-cell. , 1989, Progress in biophysics and molecular biology.

[13]  M. Magnuson,et al.  Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut. , 1994, The Journal of biological chemistry.

[14]  G. Bray,et al.  Effects of glucose, 2-deoxyglucose, phlorizin, and insulin on food intake of lean and fatty rats. , 1990, The American journal of physiology.

[15]  V. Marks,et al.  Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. , 1993, The Journal of endocrinology.

[16]  A. Buchan,et al.  Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine , 1999, Cell and Tissue Research.

[17]  F. Reimann,et al.  Glucose-sensing in glucagon-like peptide-1-secreting cells. , 2002, Diabetes.

[18]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[19]  D. Drucker,et al.  Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. , 1994, Molecular endocrinology.

[20]  T. Dakka,et al.  Peptide YY, Glucagon-Like Peptide-1, and Neurotensin Responses to Luminal Factors in the Isolated Vascularly Perfused Rat Ileum. , 1998, Endocrinology.

[21]  J. Sturis,et al.  Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. , 2002, Diabetes.

[22]  P. Brubaker,et al.  Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. , 1993, Endocrinology.

[23]  B. Göke,et al.  Gastric emptying and release of incretin hormones after glucose ingestion in humans. , 1996, The Journal of clinical investigation.

[24]  J. Sturis,et al.  Bedtime Administration of NN 2211 , a Long-Acting GLP-1 Derivative , Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes , 2002 .

[25]  T. Suda,et al.  Relationship between molecular structures of sugars and their ability to stimulate the release of glucagon-like peptide-1 from canine ileal loops. , 1990, Acta endocrinologica.

[26]  J. Egan,et al.  The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. , 2002, The Journal of clinical endocrinology and metabolism.

[27]  P. Flatt,et al.  Hexose recognition by insulin-secreting BRIN-BD11 cells. , 1996, Biochemical and biophysical research communications.

[28]  T. Kato,et al.  Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption. , 1994, Digestion.

[29]  D. Drucker,et al.  Gut adaptation and the glucagon-like peptides , 2002, Gut.

[30]  D. Pipeleers,et al.  Glucose sensing in pancreatic beta-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus. , 2001, Diabetes.

[31]  A. Grossman,et al.  Cushing’s Disease in Childhood: Presentation, Investigation, Treatment and Long-Term Outcome , 2001, Hormone Research in Paediatrics.

[32]  H. Joost,et al.  The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members , 2001, Molecular membrane biology.

[33]  P. Brubaker,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Role of the Vagus Nerve in Mediating Proximal Nutrient- Induced Glucagon-Like Peptide-1 Secretion* , 2022 .

[34]  F. Sundler,et al.  Distribution and properties of glucagon immunoreactivity in the digestive tract of various mammals: An immunohistochemical and immunochemical study , 1975, Histochemistry.

[35]  B. Göke,et al.  Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. , 1995, Digestion.

[36]  J. Henquin,et al.  Triggering and amplifying pathways of regulation of insulin secretion by glucose. , 2000, Diabetes.

[37]  S. Phillips,et al.  Passage of carbohydrate into the colon. Direct measurements in humans. , 1983, Gastroenterology.

[38]  E. Wright,et al.  Glycoside Binding and Translocation in Na+-Dependent Glucose Cotransporters: Comparison of SGLT1 and SGLT3 , 2000, The Journal of Membrane Biology.

[39]  H. Vermeer,et al.  Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man , 1992, European journal of clinical investigation.

[40]  J. Miyazaki,et al.  Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets , 1993, Diabetologia.

[41]  J. Galmiche,et al.  Peptide YY release after intraduodenal, intraileal, and intracolonic administration of nutrients in rats , 1995, Pflügers Archiv.

[42]  J. Holst,et al.  Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy , 1991, Digestive Diseases and Sciences.

[43]  L. Kow,et al.  Hypothalamic glucose sensor: similarities to and differences from pancreatic beta-cell mechanisms. , 1999, Diabetes.

[44]  G. Ramadori,et al.  Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum , 1997, Acta Diabetologica.

[45]  J. Holst,et al.  Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). , 1995, Scandinavian journal of gastroenterology.

[46]  R. Murphy,et al.  The use of perfused rat intestine to characterise the glucagon-like immunoreactivity released into serosal secretions following stimulation by glucose. , 1979, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[47]  Rachel L. Batterham,et al.  Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.